All News
Exciting Data for SLE: Plenaries from #ACR22
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!
Read Article
Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1
TheDaoIndex KDAO2011 ( View Tweet)
GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5!
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan JulianSegan ( View Tweet)
Year in Review #acr22
Oral Surveillance:
With ASCVD number needed to harm 16, only 223 without ASCVD
Focus on risk stratification
@RheumNow https://t.co/tJyha1WKfR
Eric Dein ericdeinmd ( View Tweet)
ORAL surveillance the big talking factor over the last year.
NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease.
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan JulianSegan ( View Tweet)
Great start to year in review.
Beginning with JAKinibs in the much talked about ORAL Surveillance study.
Good Review of the mechanisms of action for JAKinibs
@RheumNow #ACR22 https://t.co/IF0t4uSefj
Robert B Chao, MD doctorRBC ( View Tweet)
Good grief, no! Why not get a SPECT-CT and arthroscopy on them all as well? Less is more. I will grudgingly get a plain radiograph #ACR22 https://t.co/MVx5FFRsVS
Richard Conway RichardPAConway ( View Tweet)
Abstr #0083 COVID-19 vaccine use & hesitancy among rheum pts
- 34% expressed concern for safety of primary vaccine
- 39% did not get booster due to not being told by physician
- We need to ensure pts up to date w/ vaccine including booster
https://t.co/y1vV7wbbpQ
@RheumNow #ACR22 https://t.co/gcR2yOftjq
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr #0078
Ogdie et al found that
- Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs
- Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone
@RheumNow #ACR22
https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs
Akhil Sood MD AkhilSoodMD ( View Tweet)
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
Eric Dein ericdeinmd ( View Tweet)
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/P41KybUuNw
Dr. John Cush RheumNow ( View Tweet)
Inspiring words from Dr. @cuttingforstone, "For these times, we must heed the call to adventure, find the tools & weapons never thought of before, have courage, have faith, tell our story, find our epiphanies bec this too shall pass..."
#ACR22 @RheumNow #RheumTwitter https://t.co/l3DPnIBxq6
sheila RHEUMarampa ( View Tweet)
“The Stone Age did not end because we ran out of stones, it's because we found better technology.” – Dr. A. Verghese on how we need to be smarter about the practice medicine to accomplish more without being bogged down by logistics. #scribes @cuttingforstone @rheumnow #ACR22 https://t.co/20fP8cRRrv
TheDaoIndex KDAO2011 ( View Tweet)
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
Adela Castro AdelaCastro222 ( View Tweet)
#ACR22 Abstr#0359 Is 2021 DORIS remission attainable in #lupus? Pooled analyses of Anifrolumab RCTs showed this was met in ~10% patients in treatment group vs 3% placebo. Faster and sustained too @Rheumnow https://t.co/5MY2O8i2gA https://t.co/PUeUY25JZl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Raynaud’s:
💡Primary RP is the most common
💡Autoimmune RP is rare! Other causes more common: metabolic, trauma, vibration, Buergers.
💡NMA showed that both CCB and PDE5i reduced frequency and severity of symptoms
💡Supportive measures are cornerstone!
@ACRheum @RheumNow https://t.co/tb5FEmHJDz
Adela Castro AdelaCastro222 ( View Tweet)